Century Therapeutics (IPSC) Accumulated Expenses (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Accumulated Expenses data on file, last reported at $1.5 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $1.5 million, down 86.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (down 86.33% YoY), and the FY2025 annual result was $4.6 million, down 39.87% from the prior year.
• Accumulated Expenses retreated to $1.5 million in Q1 2026 per IPSC's latest filing, from $4.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $13.4 million in Q3 2024 and troughed at $721000.0 in Q3 2022.
• A 5-year average of $6.7 million and a median of $6.5 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses slumped 90.07% in 2022, then surged 671.98% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $9.8 million in 2022, then sank by 33.99% to $6.5 million in 2023, then increased by 18.58% to $7.7 million in 2024, then sank by 39.87% to $4.6 million in 2025, then tumbled by 67.75% to $1.5 million in 2026.
• Business Quant data shows IPSC's Accumulated Expenses at $1.5 million in Q1 2026, $4.6 million in Q4 2025, and $3.5 million in Q3 2025.